基因多态性对钙离子通道阴滞剂类抗高血压药物药动学及疗效的影响  

Effect of Genetic Polymorphisms on Pharmacokinetics and Efficacy of Calcium Channel Blockers as Antihypertensivesian Review

作　　者：喻子眈 王永庆[2] 龚晓健[1] 

机构地区：[1]中国药科大学药理学教研室,江苏南京210009 [2]南京医科大学第一附属医院临床药理研究室,江苏南京210029

出　　处：《药学进展》2014年第11期819-823,共5页Progress in Pharmaceutical Sciences

基　　金：江苏省"六大高峰人才"项目资助(No.2014-YY-001);江苏省卫生厅医学重点人才项目(No.RC201170;H201108)

摘　　要：钙离子通道阻滞剂是常用的一种高血压治疗药物,其中又以二氢吡啶类钙离子通道阻滞剂为主要代表,常见的有硝苯地平、氨氯地平、非洛地平等。然而,不同的患者个体对此类抗高血压药物可产生不同的降压效果,这种差异是环境和遗传共同作用的结果。基因多态性决定了药物代谢酶、转运体以及作用受体的差异,是导致药物疗效差异的重要原因之一。综述药物代谢酶、转运体和作用受体的基因多态性对钙离子通道阻滞剂类抗高血压药物的药动学和疗效的影响。Calcium channel blockers, especially dihydropyridine calcium channel blockers, such as nifedipine, amlodipine, l;elodipine and so on, are widely used in the therapy of hypertension. It has been revealed that there is the i nterindividual variation of efficacy among these antihypertensives in hypertension patients which is the result of variety of genetic and environmental factors and genetic polymorphisms and determines the difference of metabolic enzymes, transporters and receptors for the drugs, thus becoming one of the main reasons for the variation of efficacy of the drugs. The impact of genetic polymorphisms of the metabolic enzymes, transporters and receptors on the pharmacokinetics and efficacy of calcium channel blockers as antihepertensives was reviewed.

关 键 词：钙离子通道阻滞剂 基因多态性 药动学 抗高血压疗效 个体差 

分 类 号：R544.1[医药卫生—心血管疾病]